Journal of Clinical Medicine (Jan 2024)

Post-Irradiation Breast Angiosarcoma: All the Possible Treatments and Electrochemotherapy. Case Report and Literature Review

  • Simona Parisi,
  • Claudio Gambardella,
  • Francesco Iovino,
  • Roberto Ruggiero,
  • Francesco Saverio Lucido,
  • Giusiana Nesta,
  • Salvatore Tolone,
  • Luigi Brusciano,
  • Francesca Fisone,
  • Federico Maria Mongardini,
  • Giovanni Cozzolino,
  • Carminia Maria Della Corte,
  • Stefania Napolitano,
  • Michele Orditura,
  • Rosetta Esposito,
  • Ludovico Docimo

DOI
https://doi.org/10.3390/jcm13020567
Journal volume & issue
Vol. 13, no. 2
p. 567

Abstract

Read online

Breast angiosarcoma is a rare malignancy, accounting for less than 1% of all soft tissue cancers. It comprises primitive and secondary subtypes, such as radiogenic breast angiosarcoma (RAS). Despite multimodal treatment, angiosarcomas represent an incurable disease for many patients and a significant cause of deterioration in their quality of life. Surgery is a cornerstone in management, but high recurrence rates are reported. Electrochemotherapy (ECT) is a practicable locoregional treatment for patients with advanced angiosarcoma as part of a multimodal therapeutic strategy. The palliative benefits of ECT include optimal patient compliance, good local hemostasis control, and positive local responses. Since only 22 cases are described in the literature, we reported a rare case of RAS treated with ECT after a multidisciplinary approach, including Next Generation Sequencing (NGS). A literature review on the feasibility of ECT in RAS management was also performed.

Keywords